Clinical advances in therapies targeting the interleukin-2 receptor.
Church
A C
AC
Department of Respiratory Medicine, Glasgow Royal Infirmary, UK. colinchurch@zoom.co.uk
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001327:Autoimmune Diseases / Q000188:drug therapy; D000077552:Basiliximab; D000077561:Daclizumab; D006084:Graft Rejection / Q000188:drug therapy; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000737:chemistry / Q000627:therapeutic use; D051379:Mice; D018345:Mice, Knockout; D009369:Neoplasms / Q000188:drug therapy; D015375:Receptors, Interleukin-2 / Q000737:chemistry / Q000276:immunology* / Q000502:physiology; D011993:Recombinant Fusion Proteins; D015398:Signal Transduction
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D000077561:Daclizumab